TY - JOUR
T1 - Sonorheometry assessment of platelet function in cardiopulmonary bypass patients
T2 - Correlation of blood clot stiffness with platelet integrin αiIbβ3 activity, aspirin usage, and transfusion risk
AU - Viola, Francesco
AU - Lin-Schmidt, Xiefan
AU - Bhamidipati, Castigliano
AU - Haverstick, Doris M.
AU - Walker, William F.
AU - Ailawadi, Gorav
AU - Lawrence, Michael B.
N1 - Funding Information:
The work has been supported by a grant from the Wallace H. Coulter Foundation for Translational Medicine at the University of Virginia and NIH R01-EB005433 . The sponsors had no influence on the conduct of the research, preparation of the manuscript, data collection, analysis or interpretation of the data, or in the decision to submit the article for publication.
Publisher Copyright:
© 2015 Elsevier Ltd. All rights reserved.
PY - 2015/7/22
Y1 - 2015/7/22
N2 - Background Impaired platelet function may underlie bleeding associated with cardiopulmonary bypass (CPB) and at present is incompletely evaluated with existing diagnostic technologies. Sonorheometry (SR) is a recently developed ultrasound-based technology that quantifies hemostasis and platelet activity from a blood sample by measuring ex vivo clot stiffness (S). We hypothesized that impaired platelet-fibrin interactions as assessed by SR would correlate with transfusion during CPB and history of prior aspirin therapy. Methods Thirty-nine patients undergoing elective cardiopulmonary bypass (CPB) were enrolled following informed consent (University of Virginia IRB#14050) in a prospective observational pilot study to assess pre-operative platelet function and transfusion frequency. To assess platelet activity, abciximab was added to blood prior to SR and native S versus abciximab treated S created a differential test for platelet activity. Patient blood samples were activated with kaolin and SR was then used to measure clot stiffness. Patients were transfused with blood products as directed by clinical practice, with the surgical team blinded to SR results. Results Blood clot stiffness with and without abciximab, was compared in a ratio test (S/Sabciximab) named the Platelet Function Index (PFI). PFI was hypothesized to be positively correlated with platelet contributions through integrin αIIbβ3 to clot stiffness. PFI for CPB subjects was lower for those receiving transfusions than those not receiving transfusions (p < 0.006). A receiver-operator characteristics (ROC) analysis correlating the PFI with the blinded surgical team's decision on transfusions that included platelet concentrates generated an area under the curve (AUC) of 0.79 (p < 0.001). Additionally, the mean value of PFI for subjects on aspirin therapy was lower than for those not on aspirin therapy (p < 0.02) and correlated with a 1.73-fold enhanced risk of receiving a peri-operative transfusion. Conclusion Evaluation of platelet function with SR may help in the specification of blood transfusion needs in cardiac surgery and in the assessment of aspirin effects on risk of surgical bleeding.
AB - Background Impaired platelet function may underlie bleeding associated with cardiopulmonary bypass (CPB) and at present is incompletely evaluated with existing diagnostic technologies. Sonorheometry (SR) is a recently developed ultrasound-based technology that quantifies hemostasis and platelet activity from a blood sample by measuring ex vivo clot stiffness (S). We hypothesized that impaired platelet-fibrin interactions as assessed by SR would correlate with transfusion during CPB and history of prior aspirin therapy. Methods Thirty-nine patients undergoing elective cardiopulmonary bypass (CPB) were enrolled following informed consent (University of Virginia IRB#14050) in a prospective observational pilot study to assess pre-operative platelet function and transfusion frequency. To assess platelet activity, abciximab was added to blood prior to SR and native S versus abciximab treated S created a differential test for platelet activity. Patient blood samples were activated with kaolin and SR was then used to measure clot stiffness. Patients were transfused with blood products as directed by clinical practice, with the surgical team blinded to SR results. Results Blood clot stiffness with and without abciximab, was compared in a ratio test (S/Sabciximab) named the Platelet Function Index (PFI). PFI was hypothesized to be positively correlated with platelet contributions through integrin αIIbβ3 to clot stiffness. PFI for CPB subjects was lower for those receiving transfusions than those not receiving transfusions (p < 0.006). A receiver-operator characteristics (ROC) analysis correlating the PFI with the blinded surgical team's decision on transfusions that included platelet concentrates generated an area under the curve (AUC) of 0.79 (p < 0.001). Additionally, the mean value of PFI for subjects on aspirin therapy was lower than for those not on aspirin therapy (p < 0.02) and correlated with a 1.73-fold enhanced risk of receiving a peri-operative transfusion. Conclusion Evaluation of platelet function with SR may help in the specification of blood transfusion needs in cardiac surgery and in the assessment of aspirin effects on risk of surgical bleeding.
UR - http://www.scopus.com/inward/record.url?scp=84949636600&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949636600&partnerID=8YFLogxK
U2 - 10.1016/j.thromres.2015.11.036
DO - 10.1016/j.thromres.2015.11.036
M3 - Article
C2 - 26688324
AN - SCOPUS:84949636600
SN - 0049-3848
VL - 138
SP - 96
EP - 102
JO - Thrombosis Research
JF - Thrombosis Research
ER -